1
|
Shemer A, Scheyltjens I, Frumer GR, Kim JS, Grozovski J, Ayanaw S, Dassa B, Van Hove H, Chappell-Maor L, Boura-Halfon S, Leshkowitz D, Mueller W, Maggio N, Movahedi K, Jung S. Interleukin-10 Prevents Pathological Microglia Hyperactivation following Peripheral Endotoxin Challenge. Immunity 2020; 53:1033-1049.e7. [PMID: 33049219 DOI: 10.1016/j.immuni.2020.09.018] [Citation(s) in RCA: 72] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Revised: 08/06/2020] [Accepted: 09/23/2020] [Indexed: 01/08/2023]
Abstract
Microglia, the resident macrophages of the brain parenchyma, are key players in central nervous system (CNS) development, homeostasis, and disorders. Distinct brain pathologies seem associated with discrete microglia activation modules. How microglia regain quiescence following challenges remains less understood. Here, we explored the role of the interleukin-10 (IL-10) axis in restoring murine microglia homeostasis following a peripheral endotoxin challenge. Specifically, we show that lipopolysaccharide (LPS)-challenged mice harboring IL-10 receptor-deficient microglia displayed neuronal impairment and succumbed to fatal sickness. Addition of a microglial tumor necrosis factor (TNF) deficiency rescued these animals, suggesting a microglia-based circuit driving pathology. Single cell transcriptome analysis revealed various IL-10 producing immune cells in the CNS, including most prominently Ly49D+ NK cells and neutrophils, but not microglia. Collectively, we define kinetics of the microglia response to peripheral endotoxin challenge, including their activation and robust silencing, and highlight the critical role of non-microglial IL-10 in preventing deleterious microglia hyperactivation.
Collapse
Affiliation(s)
- Anat Shemer
- Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel
| | - Isabelle Scheyltjens
- Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium
| | - Gal Ronit Frumer
- Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel
| | - Jung-Seok Kim
- Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel
| | - Jonathan Grozovski
- Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel
| | - Serkalem Ayanaw
- Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel
| | - Bareket Dassa
- Bioinformatics Unit, Life Science Core Facilities, Weizmann Institute of Science, Rehovot 76100, Israel
| | - Hannah Van Hove
- Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium
| | | | | | - Dena Leshkowitz
- Bioinformatics Unit, Life Science Core Facilities, Weizmann Institute of Science, Rehovot 76100, Israel
| | - Werner Mueller
- Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PT, UK
| | - Nicola Maggio
- Department of Neurology, The Chaim Sheba Medical Center, Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, 5262 Tel Aviv, Israel
| | - Kiavash Movahedi
- Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium
| | - Steffen Jung
- Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.
| |
Collapse
|